Quantitative determination of sulfisoxazole and its three N-acetylated metabolites using HPLC–MS/MS, and the saturable pharmacokinetics of sulfisoxazole in mice

Electrochemical Analysis of Sulfisoxazole Using Glassy Carbon Electrode (GCE) and MWCNTs/Rare Earth Oxide (CeO2 and Yb2O3) Modified-GCE Sensors

In this work, new electrochemical sensors based on the modification of glassy carbon electrode (GCE) with multiwalled carbon nanotubes (MWCNTs)-rare metal oxides (REMO) nanocomposites were fabricated by drop-to-drop method of MWCNTs-REMO dispersion in ethanol. REMO nanoparticles were synthesized by precipitation followed by hydrothermal treatment at 180 °C in absence and presence of TritonTM X-100 surfactant. Cyclic voltammetry (CV) analysis using MWCNTs-CeO2@GCE and MWCNTs-Yb2O3@GCE sensors were used for the analysis of sulfisoxazole (SFX) drug in water samples. The results of CV analysis showed that MWCNTs-REMO@GCE sensors have up to 40-fold higher sensitivity with CeO2 compared to the bare GCE sensor. The estimated values of the limit of detection (LoD) of this electrochemical sensing using MWCNTs-CeO2@GCE and MWCNTs-Yb2O3@GCE electrodes reached 0.4 and 0.7 μM SFX in phosphate buffer pH = 7, respectively. These findings indicate that MWCNTs-REMO@GCE electrodes are potential sensors for analysis of sulfonamide drugs in water and biological samples.

Determination of sulfonamides in milk and egg samples by HPLC with mesoporous polymelamine-formaldehyde as magnetic solid-phase extraction adsorbent

In this work, magnetic mesoporous polymelamine-formaldehyde composites were synthesized via a facile Schiff base reaction. The magnetic mesoporous polymelamine-formaldehyde composites combined both the properties of mesoporous polymelamine-formaldehyde and the magnetism of NH₂ -SiO₂ @Fe₃ O₄ nanoparticles, possessing high specific surface area (150.66 m² g^-1 ) and good magnetism (24.50 emu g^-1 ). The magnetic mesoporous polymelamine-formaldehyde composites were employed as magnetic adsorbent for the extraction of sulfonamides. Under optimal conditions, good linearities with correlation coefficients higher than 0.9984 were obtained between peak area and sulfonamides concentration (2-200 μg L^-1 ) with limits of detection in the range of 0.33-0.58 μg L^-1 . The established method was successfully applied for the determination of sulfonamides in egg and milk samples. The adsorption mechanisms demonstrated that the adsorption of magnetic mesoporous polymelamine-formaldehyde composites toward sulfonamides was a multilayer process, and adsorption kinetics followed the pseudo-second-order model.

Ultrasensitive electroanalytical sulfisoxazole sensors amplified with Pd-doped ZnO nanoparticles and modified with 1-hexyl-3-methyl imidazolium bis(trifluoromethylsulfonyl)imide

In this study, an electrochemical sensor has been introduced by incorporating Pd-doped ZnO nanoparticles (ZnO–Pd/NPs) into a carbon paste (CP) matrix amplified by a conductive binder (1-hexyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (1H3MIBTMSI), in this case) to determine the concentration of the sulfisoxazole (SFX) drug in urine, tablet, and pharmaceutical wastewater samples.

Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A

Inhibitors of the secretion of cancer exosomes, which promote cancer progression and metastasis, may not only accelerate exosome biology research but also offer therapeutic benefits for cancer patients. Here we identify sulfisoxazole (SFX) as an inhibitor of small extracellular vesicles (sEV) secretion from breast cancer cells through interference with endothelin receptor A (ETA). SFX, an FDA-approved oral antibiotic, showed significant anti-tumor and anti-metastatic effects in mouse models of breast cancer xenografts, the reduced expression of proteins involved in biogenesis and secretion of sEV, and triggered co-localization of multivesicular endosomes with lysosomes for degradation. We demonstrate the important role of ETA, as target of SFX, by gain- and loss-of-function studies of the ETA protein, through a direct binding assay, and pharmacological and genetic approaches. These findings may provide a foundation for sEV-targeted cancer therapies and the mechanistic studies on sEV biology.

Extracellular vesicles are released from cells and permit communication between different cell types. Here, the authors identify that the FDA approved antibiotic sulfisoxazole, can block the release of these vesicles in breast cancer cells resulting in reduced cell growth in vitro and in vivo.